|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Smith W and Khuri FR: The care of the lung
cancer patient in the 21st century: A new age. Semin Oncol 31 (2
Suppl 4). S11–S15. 2004.
|
|
3
|
Testa U, Castelli G and Pelosi E: Lung
cancers: Molecular characterization, clonal heterogeneity and
evolution, and cancer stem cells. Cancers (Basel). 10:E2482018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rizvi NA, Hellmann MD, Brahmer JR,
Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie
SA, Goldman JW, et al: Nivolumab in combination with platinum-based
doublet chemotherapy for first-line treatment of advanced
non-small-cell lung cancer. J Clin Oncol. 34:2969–2979. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mens MMJ and Ghanbari M: Cell cycle
regulation of stem cells by MicroRNAs. Stem Cell Rev. 14:309–322.
2018. View Article : Google Scholar :
|
|
6
|
Lou W, Liu J, Gao Y, Zhong G, Ding B, Xu L
and Fan W: MicroRNA regulation of liver cancer stem cells. Am J
Cancer Res. 8:1126–1141. 2018.PubMed/NCBI
|
|
7
|
Qadir MI and Faheem A: miRNA: A diagnostic
and therapeutic tool for pancreatic cancer. Crit Rev Eukaryot Gene
Expr. 27:197–204. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shomali N, Mansoori B, Mohammadi A,
Shirafkan N, Ghasabi M and Baradaran B: MiR-146a functions as a
small silent player in gastric cancer. Biomed Pharmacother.
96:238–245. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gao W, Lu X, Liu L, Xu J, Feng D and Shu
Y: MiRNA-21: A biomarker predictive for platinum-based adjuvant
chemotherapy response in patients with non-small cell lung cancer.
Cancer Biol Ther. 13:330–340. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma JG and Li XY: MicroRNAs are involved in
the toxicity of microcystins. Toxin Rev. 36:165–175. 2017.
View Article : Google Scholar
|
|
11
|
Wu QB, Sheng X, Zhang N, Yang MW and Wang
F: Role of microRNAs in the resistance of colorectal cancer to
chemoradiotherapy. Mol Clin Oncol. 8:528–532. 2018.PubMed/NCBI
|
|
12
|
Hong L, Yang Z, Ma J and Fan D: Function
of miRNA in controlling drug resistance of human cancers. Curr Drug
Targets. 14:1118–1127. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Blower PE, Chung JH, Verducci JS, Lin S,
Park JK, Dai Z, Liu CG, Schmittgen TD, Reinhold WC, Croce CM, et
al: MicroRNAs modulate the chemosensitivity of tumor cells. Mol
Cancer Ther. 7:1–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Deng H, Qianqian G, Ting J and Aimin Y:
miR-539 enhances chemosensitivity to cisplatin in non-small cell
lung cancer by targeting DCLK1. Biomed Pharmacother. 106:1072–1081.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang X, Zhu J, Xing R, Tie Y, Fu H, Zheng
X and Yu B: miR-513a-3p sensitizes human lung adenocarcinoma cells
to chemotherapy by targeting GSTP1. Lung Cancer. 77:488–494. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ju J, Chen A, Deng Y, Liu M, Wang Y, Wang
Y, Nie M, Wang C, Ding H, Yao B, et al: NatD promotes lung cancer
progression by preventing histone H4 serine phosphorylation to
activate slug expression. Nat Commun. 8:9282017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang YX, Yue Z, Wang PY, Li YJ, Xin JX,
Pang M, Zheng QY and Xie SY: Cisplatin upregulates MSH2 expression
by reducing miR-21 to inhibit A549 cell growth. Biomed
Pharmacother. 67:97–102. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang PY, Sun YX, Zhang S, Pang M, Zhang
HH, Gao SY, Zhang C, Lv CJ and Xie SY: Let-7c inhibits A549 cell
proliferation through oncogenic TRIB2 related factors. FEBS Lett.
587:2675–2681. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang YX, Yan YF, Liu YM, Li YJ, Zhang HH,
Pang M, Hu JX, Zhao W, Xie N, Zhou L, et al: Smad3-related miRNAs
regulated oncogenic TRIB2 promoter activity to effectively suppress
lung adenocarcinoma growth. Cell Death Dis. 7:e25282016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gao Y, Deng K, Liu X, Dai M, Chen X and
Chen J and Chen J, Huang Y, Dai S and Chen J: Molecular mechanism
and role of microRNA-93 in human cancers: A study based on
bioinformatics analysis, meta-analysis, and quantitative polymerase
chain reaction validation. J Cell Biochem. 120:6370–6383. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kwon Y, Kim Y, Eom S, Kim M, Park D, Kim
H, Noh K, Lee H, Lee YS, Choe J, et al:
MicroRNA-26a/-26b-COX-2-MIP-2 loop regulates allergic inflammation
and allergic inflammation-promoted enhanced tumorigenic and
metastatic potential of cancer cells. J Biol Chem. 290:14245–14266.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tan M, Wu J and Cai Y: Suppression of Wnt
signaling by the miR-29 family is mediated by demethylation of
WIF-1 in non-small-cell lung cancer. Biochem Biophys Res Commun.
438:673–679. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang PY, Li YJ, Zhang S, Li ZL, Yue Z, Xie
N and Xie SY: Regulating A549 cells growth by ASO inhibiting miRNA
expression. Mol Cell Biochem. 339:163–171. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qian Q, Sun W, Zhu W, Liu Y, Ge A, Ma Y,
Zhang Y, Zeng X and Huang M: The role of microRNA-93 regulating
angiopoietin2 in the formation of malignant pleural effusion.
Cancer Med. 6:1036–1048. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hahne JC and Valeri N: Non-Coding RNAs and
resistance to anticancer drugs in gastrointestinal tumors. Front
Oncol. 8:2262018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nagesh PKB, Chowdhury P, Hatami E, Boya
VKN, Kashyap VK, Khan S, Hafeez BB, Chauhan SC, Jaggi M and Yallapu
MM: miRNA-205 nanoformulation sensitizes prostate cancer cells to
chemotherapy. Cancers (Basel). 10:E2892018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin YS, Lin YY, Yang YH, Lin CL, Kuan FC,
Lu CN, Chang GH, Tsai MS, Hsu CM, Yeh RA, et al: Antrodia
cinnamomea extract inhibits the proliferation of
tamoxifen-resistant breast cancer cells through apoptosis and
skp2/microRNAs pathway. BMC Complement Altern Med. 18:1522018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chan LW, Wang F, Meng F, Wang L, Wong SC,
Au JS, Yang S and Cho WC: MiR-30 family potentially targeting
PI3K-SIAH2 predicted interaction network represents a novel
putative theranostic panel in non-small cell lung cancer. Front
Genet. 8:82017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao L, Li R and Gan YH: Knockdown of Yin
Yang 1 enhances anticancer effects of cisplatin through protein
phosphatase 2A-mediated T308 dephosphorylation of AKT. Cell Death
Dis. 9:7472018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cao L, Wan Q, Li F and Tang CE: MiR-363
inhibits cisplatin chemoresistance of epithelial ovarian cancer by
regulating snail-induced epithelial-mesenchymal transition. BMB
Rep. 51:456–461. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang Y, Huang S, Guo Y and Li L: MiR-1294
confers cisplatin resistance in ovarian Cancer cells by targeting
IGF1R. Biomed Pharmacother. 106:1357–1363. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Markou A, Sourvinou I, Vorkas PA, Yousef
GM and Lianidou E: Clinical evaluation of microRNA expression
profiling in non small cell lung cancer. Lung Cancer. 81:388–396.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Price C and Chen J: MicroRNAs in cancer
biology and therapy: Current status and perspectives. Genes Dis.
1:53–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sun CC, Li SJ, Zhang F, Zhang YD, Zuo ZY,
Xi YY, Wang L and Li DJ: The novel miR-9600 suppresses tumor
progression and promotes paclitaxel sensitivity in non-small-cell
lung cancer through altering STAT3 expression. Mol Ther Nucleic
Acids. 5:e3872016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang P: The cell cycle and development:
Redundant roles of cell cycle regulators. Curr Opin Cell Biol.
11:655–662. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Blanco L and Tirado CA: Testicular germ
cell tumors: A cytogenomic update. J Assoc Genet Technol.
44:128–133. 2018.PubMed/NCBI
|
|
38
|
Takano Y, Kato Y, van Diest PJ, Masuda M,
Mitomi H and Okayasu I: Cyclin D2 overexpression and lack of p27
correlate positively and cyclin E inversely with a poor prognosis
in gastric cancer cases. Am J Pathol. 156:585–594. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mermelshtein A, Gerson A, Walfisch S,
Delgado B, Shechter-Maor G, Delgado J, Fich A and Gheber L:
Expression of D-type cyclins in colon cancer and in cell lines from
colon carcinomas. Br J Cancer. 93:338–345. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sicinski P, Donaher JL, Geng Y, Parker SB,
Gardner H, Park MY, Robker RL, Richards JS, McGinnis LK, Biggers
JD, et al: Cyclin D2 is an FSH-responsive gene involved in gonadal
cell proliferation and oncogenesis. Nature. 384:470–474. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Johnson CD, Esquela-Kerscher A, Stefani G,
Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J,
Shingara J, et al: The let-7 microRNA represses cell proliferation
pathways in human cells. Cancer Res. 67:7713–7722. 2007. View Article : Google Scholar : PubMed/NCBI
|
